Kornimate/medical-research-clean huggingface dataset:
tdcs for the treatment of migraine

Conditions: Migraine Disorders

Summary: the aim of this study is to evaluate an optimized protocol of tdcs that normalize the lack of habituation and efficiency of inhibitory cortical circuits in migraine patients. for this purpose, migraineurs volunteers will undergo to optimized tdcs protocol or sham tdcs.

a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tdcs will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. electrical cortical activity will be assessed through: (i) motor evoked potential (mep); (ii) motor threshold (mt); (iii) short interval intracortical inhibition (sici); (iv) intracortical facilitation (icf); (v) phosphene threshold (pt) and (vi) visual evoked-potential (vep-habituation). clinical outcomes will be evaluated through: (i) headache diary; (ii) visual analog scale (vas); (iii) migrainde disability assessment (midas); (iv) headache impact test (hit-6) and (v) world health organization quality of life assessment instrument (whoqol bref).

Eligibility criteria:
inclusion criteria: * presented diagnostic of episodic migraine with or without aura or probably migraine with or without aura according to the criteria for diagnosis of international classification of headache disorders (ichd-iii) * disease duration of at least 12 months * without preventive medication for at least 6 months prior to initiation of treatment exclusion criteria: * pregnant women; * pacemaker; * history of seizures; * metallic implants in the head; * patients with clinical evidence of brain injuries; * chronic pain associated to others diseases; * use of neuroleptic medications

Keywords: migraine disorders transcranial direct current stimulation electric stimulation therapy pain
short-term effects of humidification devices on respiratory pattern and work of breathing during invasive ventilation

Conditions: Chronic Respiratory Failure

Summary: this study compares the short-term effects of a new humidification system (hygrovent gold) and two other humidification devices (heated and moisture exchanger and heated humidifier) on respiratory pattern and work of breathing, during invasive ventilation.

three humidifying devices are commonly and indifferently used during mechanical ventilation, but their impact on respiratory mechanics and, eventually, mechanical ventilation efficacy, particularly in patients highly dependent from mechanical ventilation, are not superimposable. it has already been described that heated and moisture exchangers (hme), increasing dead space, can negatively affect ventilatory function and gas exchange, in comparison to heated humidifiers (hh). the hygrovent gold, mainly because of its position between the tracheostomy and the y-piece of the ventilatory circuit and its structure, may lead to analogous or even worse effects, determining and increase in inspiratory resistances and dead space and consequently an increase in the work of breathing.

Eligibility criteria:
inclusion criteria: * chronic hypercapnic respiratory failure (paco2 of 45 mmhg or more) * long-term mechanical ventilation via tracheostomy * clinical stability exclusion criteria: * non collaborative subjects * acute respiratory failure * haemodynamic instability * encephalopathy

Keywords: invasive mechanical ventilation humidifying devices respiratory mechanics
pregnancy and congenital toxoplasmosis

Conditions: Congenital Toxoplasmosis; Retinochoroiditis

Summary: the toxoplasma gondii parasite causes toxoplasmosis. it is characterized by persistent cysts mostly localised in the brain and ocular areas. in the case of immunodeficiency, those cysts are likely to reactivate. during pregnancy, an infection exposes the foetus to a variety of consequences, from severe neurologic lesions to subclinical forms at birth. however, those forms are likely to complicate at any age to toxoplasmic retinochoroiditis, that can unpredictably recur with severe functional consequences. pregnancy may stimulate lesions or their recurrences, putting the foetus at risk of contamination because of the release of tachyzoites in the bloodstream. the occurrence of these complications is poorly known, especially with congenital toxoplasmosis. nevertheless, this information is essential to take care of patients, particularly women with congenital toxoplasmosis, usually worried about the consequences of a pregnancy. as a precaution, women with congenital toxoplasmosis follow a specific ophthalmologic, and trimonthly monitoring, composed of fundus examinations during pregnancy and in postpartum. to eliminate the contamination risk, serological examinations at birth and one year later are done on their kids. the aim of this study is to estimate the risk of toxoplasmic retinochoroiditis during pregnancy and the impact on their children. retrospective and prospective data from the lyon cohort of maternal and congenital toxoplasma infections will be used. as a result of to this study, the investigators expect to provide better information to women suffering from congenital toxoplasmosis about their own ocular safety during pregnancy, and the safety of their child(ren). the investigators seek to provide new national and international recommendations about these patients and their children's care.


Eligibility criteria:
inclusion criteria: * being a woman * born before march 2022 * suffering from congenital toxoplamosis exclusion criteria: * refusal to give informed consent * any condition that would limit the ability of the patient to give consent * psychiatric cares * to be deprived of liberty * to be under administrative supervision
fecal microbial transplantation in critically ill patients with severe infections.

Conditions: Sepsis; Infections

Summary: fecal microbial transplantation is to transplant functional microbiota from the feces of healthy people into the gastrointestinal tract of patients, reconstruct new intestinal microbiota, and realize the treatment of intestinal and extra-intestinal diseases. compared with ordinary commercial probiotics, fmt is more consistent with the composition of the intestinal microecological structure and can recover intestinal flora to the maximum extent and faster. fmt increases intestinal bacteria production function and helps to restore the systemic immune response so that sepsis pathogens are removed. the aim of this trial was to investigate the clinical effect of fmt in the treatment of patients with severe infections.

the gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° c, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. the other treatment measures were the same as those of the control group.

Eligibility criteria:
inclusion criteria: * patients diagnosed with severe infections, which is infected patients safa≥2 or apache ⅱ≥15 * aged ≥14 years * patients or their family members agreed to participate in this study exclusion criteria: * advanced tumors or diseases associated with systemic immunosuppression * pregnant women * patients with severe intestinal ulcer or perforation * unable to complete oral administration and no effective artificial feeding pipeline.
evaluation of potential vitamin d effects on muscle: a pilot study

Conditions: Dysphagia; Fecal Incontinence; Urinary Incontinence

Summary: people who do not have adequate amounts of vitamin d develop weakness of leg and arm muscles. this study will determine if vitamin d supplementation benefits muscle functions important for swallowing, bladder and bowel function.


Eligibility criteria:
inclusion criteria: * patients who present for evaluation to the uw geriatric clinic including dr. pryzbelski's subspecialty, or osteoporosis clinics * age 70 years or older * cognitively intact, as determined by the attending physicians at above mentioned clinics exclusion criteria: * history of, on ongoing, renal failure * history of liver failure * known malabsorption * known disorders of parathyroid function, hyper/hypocalcemia, or other abnormalities of calcium or phosphate metabolism * known history of vitamin d intoxication or granulomatous disease * active seizure disorder * pain associated with temporomandibular joint (tmj)
velcade® (bortezomib) with rituximab in subjects with relapsed or refractory indolent b-cell lymphoma

Conditions: B-Cell Lymphoma; Follicular Lymphoma; Marginal Lymphoma

Summary: the purpose of this study is to evaluate the safety and effectiveness of velcade when given in combination with rituximab in patients with relapsed or refractory indolent b-cell lymphoma. this study will investigate if treatment with velcade and rituximab increases the time it takes your lymphoma to get worse.


Eligibility criteria:
inclusion criteria: * male or female subject 18 years or older * diagnosis of b-cell lymphoma (cd20+) of * follicular lymphoma (grades 1, 2, and 3) or * marginal zone lymphoma (extranodal, nodal, and splenic) * documented relapse or progression following prior anti-neoplastic treatment. * at least 1 measurable lymph node mass that is \>1.5 cm. * no active cns lymphoma * voluntary consent exclusion criteria: * previous treatment with velcade * any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug. * any treatment with nitrosoureas within 6 weeks before the first dose of study drug. * treatment with zevalin™ or bexxar® within 10 weeks before the first dose of study drug. * rituximab, campath® or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug. * radiation therapy within 3 weeks before the first dose of study drug. * major surgery within 2 weeks before the first dose of study drug. * peripheral neuropathy or neuropathic pain * history of allergic reaction attributable to compounds containing boron or mannitol * known anaphylaxis or hypersensitivity to any component of rituximab * diagnosed or treated for a selected malignancies other than nhl within 5 years. * active systemic infection requiring treatment * female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study. * male subjects who do not agree to use an acceptable method of contraception for the duration of the study * any serious medical or psychiatric illness likely to interfere with participation in this clinical study * concurrent treatment with another investigational agent. concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.

Keywords: lymphoma non-hodgkin's nhl b-cell indolent
blood collection for research related to certain diseases involving blood vessels

Conditions: Sickle Cell Disease

Summary: the collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical research studies. this protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed.

the collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical research studies. this protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed.

Eligibility criteria:
* inclusion criteria: males or females of age 18 years and older can be included in the study. exclusion criteria: individuals without sickle cell disease or other chronic anemias who wish to donate blood will be excluded if the hemoglobin is less than 10 g/dl for women or less than 12g/dl for men. individuals with sickle cell disease or other chronic anemias will be excluded from donating blood samples if the hemoglobin is less than 6 g/dl. a participant s most recent cbc result, obtained in the past 12 months, will be used to determine eligibility. there are no exclusion criteria for participants donating saliva or urine.

Keywords: dna endothelial function leukocyte gene expression rna natural history sickle cell coronary artery disease cad healthy volunteer hv
safety and efficacy study of nimotuzumab plus neoadjuvant and concurrent chemoradiotherapy to treat oropharynx and hypopharynx cancer

Conditions: Oropharyngeal Cancer; Hypopharyngeal Cancer

Summary: the purpose of this study is to evaluate the efficiency and safety of adding nimotuzumab to neoadjuvant and concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced squamous cell carcinoma of the oropharynx and hypopharynx.

locoregionally advanced squamous cell carcinoma of the head and neck(la-scchn) poses one of the most complex management challenges. this stage of disease is still potentially curable, but requires combined-modality therapy. recent studies have showed that induction chemotherapy（neoadjuvant）reduced the 3-year distant relapse rate. concurrent chemoradiotherapy(ccrt), on the other hand, has demonstrated a significant and consistent benefit in local control rates, but its impact on distant failure is inconsistent. nimotuzumab is a novel egfr-targeting monoclonal antibody that has the potential.to be used as a single agent or as a radio- and chemotherapy sensitizer for the treatment of scchn. thus, investigators conducted a randomized, multicenter phaseⅱ study to compare the efficiency and safety of adding nimotuzumab to neoadjuvant and ccrt with neoadjuvant and ccrt in the treatment of patients with locoregionally advanced squamous cell carcinoma of the oropharynx and hypopharynx.

Eligibility criteria:
inclusion criteria: * informed consent form * histologically confirmed locally advanced (stages iii and ivb), squamous cell carcinoma of the oropharynx and hypopharynx * the tumor mass had to be measurable * karnofsky performance status ≥70 * life expectancy estimated than 6 months * hematologic: wbc≥4×109 /l , plateletes≥100×109 /l, haemoglobin ≥100 g/l； * hepatic: ast/alt\<1.5 times upper limit of normal (uln)；serum bilirubin\<1.5 times uln; * renal: creatinine\<1.5 times uln； exclusion criteria: * known distant metastases * primary tumor and nodes received surgery(except of biopsy) * received other anti egfr monoclonal antibody treatment * previous chemotherapy or radiotherapy * participation in other interventional clinical trials within 1 month * other malignant tumor (except of non-melanoma skin cancer or carcinoma in situ of cervix) * history of serious allergic or allergy * history of serious lung or heart disease * pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant

Keywords: neoadjuvant concurrent chemoradiotherapy,ccrt nimotuzumab locoregionally advanced oropharynx hypopharynx cancer randomized multicenter
prospective cohort study of neoadjuvant therapy with sintilimab (pd-1 inhibitor) combined with chemotherapy in resectable escc

Conditions: Resectable Esophageal Squamous Cell Carcinoma

Summary: this study is an open-label, prospective, cohort clinical study to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer. in the study, all subjects who meet the enrollment criteria will be randomized 1:1:1 to receive sintilimab combined with platinum-containing chemotherapy q3w for 3 cycles (group a), sintilimab combined with platinum-containing chemotherapy q3w for 2 cycles + sintilimab for 1 cycle (group b), sintilimab combined with platinum-containing chemotherapy for 1 cycle + sintilimab q3w for 2 cycles (group b) as neoadjuvant therapy, and receive radical surgery within 4-6 weeks after the completion of the last neoadjuvant therapy. whether the subjects need adjuvant therapy and adjuvant treatment regimen after surgery are determined by the investigator, and all subjects need to complete the follow-up plan formulated by the study after surgery.


Eligibility criteria:
inclusion criteria: 1. preoperative gastroscopy showed that the main body of the tumor was located. 2. patients with potentially resectable esophageal cancer evaluated by preoperative imaging (chest contrast-enhanced ct, head ct or mri, abdominal b-ultrasound, pet/ct), and the potentially resectable patients refer to the 2018 edition of the diagnosis and treatment standards for esophageal cancer formulated by the national health and wellness commission, defined as patients with esophageal cancer stage t2-3, n0/n+, m0 or t4a, n0-1, m0 (8th edition ajcc stage in 2017). 3. signed informed consent and met all the inclusion criteria of this study. 4）aged 18\~75 years old 5）ecog ps score of 0-1; exclusion criteria: 1. prior treatment with immune checkpoint inhibitors, including but not limited to anti-ctla-4, anti-pd-1 and anti-pd-l1 therapeutic antibodies, and ox-40; 2. .previous systemic therapy; 3. current participation in an interventional clinical trial or receipt of another investigational drug or medical intervention within 4 weeks; 4. presence of active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction (or other factors affecting the absorption of oral medications such as inability to swallow, nausea and vomiting, abnormal physiologic function, malabsorption syndrome, etc.) that require clinical intervention 5. the presence of any signs or history of bleeding constitution; the presence of unhealed wounds, ulcers, or fractures in patients who have experienced any bleeding or hemorrhagic event ≥ ctcae grade 3 within 4 weeks prior to enrollment; -

Keywords: neoadjuvant therapy pd-1 inhibitor resectable esophageal squamous cell carcinoma
chlorhexidine gluconate for prevention of ventilator associated pneumonia in children.

Conditions: Mechanical Ventilation for More Than 48 Hours.

Summary: to determine the efficacy of prophylaxis with 0.12% chlorhexidine gluconate compared with placebo to prevent ventilator associated pneumonia in children admitted to a pediatric critical care unit.

randomised controlled trial to determine the efficacy of 0.12% chlorhexidine gluconate compared with placebo to prevent ventilator associated pneumonia in children admitted to a pediatric critical care unit.

Eligibility criteria:
inclusion criteria: * children aged 1 month to 18 years admitted to the intensive care unit. * intubated for more than 48 hours. exclusion criteria: * clinical or radiological diagnosis of pneumonia previous to the endotracheal intubation. * allergy to chlorhexidine. * known immune deficiency. elimination criteria: * transfer to another hospital.
arm pump in motorcross training

Conditions: Healthy Individuals; Patients With Arm Pump

Summary: arm pump is a sport specific term drivers use to describe acute or chronic compartment syndrome of the forearm. drivers experience pain in the forearms due to increased blood pressure in forearm muscle compartments. no strategies nor methods have been used to diminish the risk to suffer from arm pump within motor cross. this project aims to look at ergonomics of driving and its relationship with the occurrence of arm pump. the investigators will first investigate the experience of motor cross athletes with arm pump through motor cross federations in belgium and the netherlands (survey). two groups of athletes will be selected (20 persons within each group) who will be invited to the motor cross track to investigate their hand grip strength, motor driving position, muscle activity.


Eligibility criteria:
inclusion criteria: * recreational or competitive motor cycling athletes * with or without arm pump problems * signing informed consent * participation with their own motor bike * regular training hours exclusion criteria: * inactive for more than 2 weeks before participation * pathology at shoulder, elbow or wrist level (except for arm pump)
ribavirin dose optimization for the treatment of hepatitis c

Conditions: Chronic Hepatitis C

Summary: patients for whom treatment with peginterferon plus ribavirin was unsuccessful represent a category of patients for whom there is currently no worthwhile therapeutic alternative. several studies have shown that there is a relation between plasma ribavirin concentrations and treatment response. adequate ribavirin plasma concentrations, especially during the first 12 weeks of treatment, should be associated with a better chance of response to the treatment. the strategy for this study will be to use a loading dose of ribavirin before beginning the treatment with peg-interferon, thereby allowing for optimal ribavirin concentrations to be reached, and possibly improving the effectiveness of the treatment.


Eligibility criteria:
inclusion criteria: * age \> 18 years * chronic hepatitis c and failure of prior treatment with peginterferon plus ribavirin (non-response: hcv-rna decreased less than 2 logs after 3 months of treatment; relapse: hcv-rna that becomes positive again after treatment is stopped * compensated hepatic disease (child-pugh ≤ 6) * provision by patient of his or her written consent exclusion criteria: * females who are pregnant or lactating will be excluded * renal failure (estimated glomerular filtration rate \< 50 ml/min) * a contraindication to treatment with peginterferon plus ribavirin (uncontrolled psychiatric illness, pregnancy/nursing/non-use of effective contraceptive method, uncontrolled epilepsy for at least 6 months, heart failure, unstable angina, hemoglobin \< 120 g/l, neutrophils \< 1,000/mm3, platelets \< 50 x 109/l, or any other condition that, in the investigator's opinion, contraindicates use of the treatment)

Keywords: ribavirin pegasys hepatitis
a study of ci-1012 in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give ci-1012 to hiv-infected patients who do not have any symptoms of the disease. this study also examines how the body handles ci-1012.

patients receive 2 weeks of oral ci-1012 therapy in this open-label study, with 8 patients entered at each dose level studied.

Eligibility criteria:
inclusion criteria patients must have: * serologic evidence of infection with hiv-1. * cd4+ cell count \>= 200 cells/mm3. * hiv-1 rna \>= 10,000 copies/ml. exclusion criteria co-existing condition: patients with the following conditions are excluded: viral, fungal, or bacterial infection requiring therapy other than topical medications. concurrent medication: excluded: * prophylactic systematic antibacterial, antifungal or antiviral agents. * antiretroviral therapy. note: * patient must be willing to remain off antiretroviral therapy for 1 week after completing study medication. prior medication: excluded: * experimental therapy for \>= 4 weeks prior to initiation of study medication. * antiretroviral treatment for 3 weeks prior to initiation of study medication. * systemic steroids or anticancer agents for 4 weeks prior to initiation of study medication.

Keywords: dose-response relationship, drug administration, oral drug administration schedule cd4 lymphocyte count anti-hiv agents